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Abstract
We used the World Health Organization’s Composite International Diagnostic Interview to determine the prevalence, comorbidity, and correlates of lifetime and 12-month behavioral health disorders in a multisite cohort of 1027 women living with
HIV in the United States. Most (82.6%) had one or more lifetime disorders including 34.2% with mood disorders, 61.6%
with anxiety disorders, and 58.3% with substance use disorders. Over half (53.9%) had at least one 12-month disorder,
including 22.1% with mood disorders, 45.4% with anxiety disorders, and 11.1% with substance use disorders. Behavioral
health disorder onset preceded HIV diagnosis by an average of 19 years. In multivariable models, likelihood of disorders was
associated with women’s race/ethnicity, employment status, and income. Women with 12-month behavioral health disorders
were significantly more likely than their counterparts to engage in subsequent sexual and substance use HIV risk behaviors.
We discuss the complex physical and behavioral health needs of women living with HIV.
Keywords Psychiatric epidemiology · Women living with HIV · Mental illness · Substance use disorder · Prevalence of
behavioral health disorder
Resumen
Utilizamos la Entrevista Diagnóstica Internacional Compuesta de la Organización Mundial de la Salud para determinar
la prevalencia, la comorbilidad y los correlatos de trastornos de salud conductual de la vida y de 12 meses en una cohorte
multisitio de 1.027 mujeres que viven con VIH en los Estados Unidos. La mayoría (82.6%) tuvo uno o más trastornos en su
vida, incluyendo 34.2% con trastornos del estado de ánimo, 61.6% con trastornos de ansiedad y 58.3% con trastornos por el
uso de las sustancias. Más de la mitad (53.9%) tuvo al menos un trastorno en los últimos 12 meses, incluyendo 22.1% con
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trastornos del estado de ánimo, 45.4% con trastornos de ansiedad y 11.1% con trastornos por el uso de las sustancias. El
inicio del trastorno de salud conductual precedió el diagnóstico de VIH en un promedio de 19 años. En modelos multivariables, la probabilidad de trastornos se asoció con la raza/etnia de las mujeres, el estado de empleo y los ingresos. Las mujeres
con trastornos de salud conductual de 12 meses fueron considerablemente más probable que sus homólogas a participar en
comportamientos de riesgo de VIH como el uso de las sustancias y conductas sexuales de riesgo. Discutimos las necesidades
complejas de salud física y conductual de las mujeres que viven con el VIH.

Introduction
In the US, the prevalence of psychiatric disorders and
substance use disorders among people living with HIV is
thought to be high [1–3]. However, estimates typically are
derived from small, non-representative samples because
population-based studies are rare, and most research uses
screening rather than full diagnostic assessment. Moreover,
prior research has addressed a limited range of specific disorders or diagnostic groupings, with few reports on a comprehensive array of psychiatric disorders and substance use
disorders. The purpose of this study was to determine the
prevalence, comorbidity and correlates of a full range of
behavioral health disorders in a longitudinal multisite cohort
of women living with HIV participating in the Women’s
Interagency HIV Study or WIHS.
To date, the sole nationally representative study of
behavioral health disorders among HIV-positive US adults
is the 1996–1997 HIV Cost and Services Utilization Study
(HCSUS) [4]. Using the Composite International Diagnostic Interview (CIDI) Short Form, HCSUS participants were
screened for major depression, dysthymia, generalized anxiety disorder, and panic disorders in the past year [5]. Close
to half screened positive for one or more of these psychiatric
disorders (47.9% of the weighted sample). The full CIDI
diagnostic interview was administered separately to a subsample of the original cohort, and results were used to refine
prevalence estimates [6] resulting in a 32.8% prevalence of
any 12-month psychiatric disorder: 22.0% for major depression; 5.0% for dysthymia; 4.1% for generalized anxiety disorder; and 15.5% for panic disorder. While lower than those
obtained by screening, these estimates were considerably
higher than those found in a survey of the general population which used the full CIDI and found prevalence rates of
26.2% for any psychiatric disorder, 6.7% for major depression, 1.5% dysthymia, 3.1% generalized anxiety disorder,
and 2.7% panic disorder [7, 8].
Clinical studies of smaller, non-representative samples
report the prevalence for any current psychiatric disorder
of 33–63% among HIV-positive adults [9–13]. Research
on depressive disorders finds prevalence estimates ranging
from 10 to 20% [11, 14]. Anxiety disorders also are prevalent, with estimates ranging from 5 to 15%, with the most
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common being generalized anxiety disorder and social anxiety disorder [9, 14, 15].
Information about the prevalence of substance use disorders among HIV-positive individuals is also lacking [1–3].
In the HCSUS CIDI-Short Form screening study, 50.1% of
participants reported illicit drug use in the past year and 12%
met criteria for drug dependence [5]. Close to a fifth (18.5%)
met criteria for alcohol use disorders [4].
High rates of co-occurring psychiatric disorders and substance use disorders are reported among people living with
HIV [10, 16, 17]. In the HCSUS, the 12-month prevalence
of co-occurring disorders was 10% [18, 19]. Also in the
HCSUS, multivariable analysis revealed that the presence
of any psychiatric disorder was significantly associated with
drug dependence, and vice versa [5]. However, there is very
little information on co-occurrence of substance use disorders with specific psychiatric syndromes, which inhibits our
understanding of how these conditions interact, and their
impact on HIV transmission behaviors and outcomes [20].
Turning next to HIV-positive women, a longitudinal
multisite study of 1223 HIV-infected birth mothers found
that 32% screened positive for psychiatric disorder, 9% for
substance use disorder, and 35% for psychiatric disorder
and/or substance use disorder [21]. Another study examined electronic medical records of HIV-positive patients
in California, including 738 women, in which psychiatric
disorder and substance use disorder diagnoses were based
on clinician judgment and patient self-report [22]. In this
study, 50% of female patients had a documented psychiatric
disorder, including 25% with a mood disorder, 16% with
an anxiety disorder and 12% with a substance use disorder.
Among 1710 participants in the longitudinal multisite HIVpositive WIHS cohort, 55% met criteria for probable depression [23] and they also reported high rates of alcohol [24]
and substance use [25]. These comorbidities often occur in
a context of poverty, trauma, housing instability, caregiving
demands, racial/ethnic discrimination, and multiple health
needs [26–28].
A number of studies have documented associations
between behavioral health disorders and engaging in HIV
transmission behaviors [29, 30]. These include sexual risk
behaviors such as unprotected sex [31], having multiple
sex partners [32], and receptive anal intercourse [33]. Also
included are drug-related risk behaviors such as sharing
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needles [34], and exchanging sex for drugs, money or other
material items [34, 35]. An even greater likelihood of HIV
risk behaviors has been observed among people with cooccurring substance use disorders and psychiatric disorders
[36–38], including major depressive disorder [39] and posttraumatic stress disorder [40]. Moreover, while awareness
of one’s HIV positive serostatus appears to decrease the
likelihood of engaging in risk behaviors [41] even among
those with psychiatric and/or substance use disorders [42],
a noteworthy proportion of individuals living with HIV continue to engage in high-risk sex and drug use behaviors [43],
creating opportunities for viral transmission to uninfected
individuals [44].
Given the foregoing research findings and the remaining
gaps in our knowledge, the present study addressed three
major research questions. First, what are the lifetime and
12-month prevalence and severity of a full range of DSM-IV
disorders in a multisite study cohort of women living with
HIV, and what syndromes are most frequently comorbid?
Second, what are the individual correlates associated with
psychiatric disorders and substance use disorders among
these women? And third, are specific behavioral health disorders, including co-occurring conditions, associated with
a greater likelihood of engaging in HIV risk behaviors, controlling for confounding factors?

Methods
Study Participants
The WIHS is a multisite cohort study of women living with
or at risk of acquiring HIV infection recruited in the mid1990s at six US sites: Brooklyn, Bronx, Chicago, Los Angeles, San Francisco/Bay Area, and Washington, DC. Details
of the WIHS cohort and study design can be found in prior
publications [45, 46].
For this nested study, inclusion criteria were being an
active HIV-positive WIHS participant, able to understand
spoken English, and capable of completing an in-person
assessment. From 2010 through 2013, 1213 Englishspeaking women were approached and 1033 consented to
participate (85.2%), providing written informed consent
using procedures approved by the University of Illinois at
Chicago (UIC) Institutional Review Board (IRB), and the
IRBs at each study site. Data for this analysis include 1027
women, representing 74.2% of the 1385 who were active as
of 2010. The remaining 358 women were not included for
the following reasons: unfinished interviews (n = 6); active
refusals (n = 60); passive refusals whom we were unable
to locate or schedule (n = 126); and exclusively Spanishlanguage speakers (n = 166). Comparisons between the
1027 study participants and the remaining 358 found no
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significant differences in age, education, income, marital
status, CD4 + cell count, HIV-1 viral load, or use of combination antiretroviral therapy (cART). However, compared
to the remaining 358 non-participants, a larger proportion
of study completers were African American (78.4% vs.
64.4% of non-completers, Chi square = 13.91, p < 0.001),
and not employed (68.2% vs. 55.5% of non-completers, Chi
square = 11.71, p = 0.001). At all but one site, response
rates ranged from 71 to 89%, with the remaining site (Los
Angeles) having a low response rate of 40% due to the high
concentration of Spanish-only speakers.

Measures
WIHS research interviewers from each site completed 3 days
of training on the use of the World Health Organization
CIDI 3.0 Auto Version, a comprehensive, fully standardized
battery that assessed disorders according to the criteria of
the DSM-IV, hereafter referred to as the WMH-CIDI [47].
Training was provided by either the University of Michigan’s
WHO-designated WMH-CIDI training center or by WHOtrained UIC research staff. Interviews were administered
via laptop software programmed with skip patterns, error
screening, and consistency checks. A randomly selected 5%
of respondents were contacted via telephone by the UIC
study manager following the interview, to verify interview
process and completion.
Participant age, race/ethnicity, education, employment,
income, marital status, study site, and CD4+ cell count were
ascertained from the WIHS semiannual study visit closest to
the WMH-CIDI assessment. Participant risk behaviors were
assessed at up to 6 semiannual visits following the WMHCIDI assessment. HIV sexual risk behavior was defined as
exchanging sex for money/drugs/shelter, multiple current
male partners, or receptive anal sex; and substance use risk
behavior was defined as use of any illicit drug or high risk
drinking defined as consumption of > 7 standard alcoholic
drinks per week in accordance with the National Institute on
Alcohol Abuse and Alcoholism [48].

Statistical Analysis
Frequency distributions and cross-tabulations were used to
calculate prevalence, severity, and comorbidity of behavioral health diagnoses in the WIHS cohort and the 2003
National Comorbidity Survey Replication (NCS-R) women’s
cohort. Prevalence and standard errors in the NCS-R data
were calculated using the study documentation manual’s
survey strata, clusters, and weights [49]. Adjusted logistic
regression analysis examined associations between participant characteristics and behavioral health disorders. Random effects logistic regression models (RRM) analyzed the
prospective relationships between 12-month diagnoses and
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HIV sexual and substance use risk behaviors. Analyses were
conducted in IBM SPSS Statistics 23 and SAS 9.4.

Results
Lifetime DSM‑IV Disorders and Age of Onset
Characteristics of the study participants are shown in
Table 1. Table 2 presents the lifetime prevalence of DSMIV disorders in our study population and compares it to that
of the US adult women’s general household population in the
NCS-R. As shown at the bottom of column 1, the majority
of our study population (82.6%) reported a lifetime DSM-IV
disorder versus just under half of the general US women’s
population (45.7%) shown in column 2. Prevalence of lifetime mood disorders in the study population was considerably higher than that of the general population (34.2% vs
23.7%) as were anxiety disorders (61.6% vs 37.0%), and
substance use disorders, which were 6 times more likely
in the study group versus the general population (58.3% vs
8.8%). The most common specific lifetime disorders were
drug abuse (49.4%), major depressive disorder (32.4%), and
posttraumatic stress disorder (PTSD) (29.8%).
The average age of onset for different DSM-IV disorders
is presented in column 3 of Table 2. The vast majority of
mood disorders, anxiety disorders, and substance use disorders had an average age of onset in the early- to mid-20s.
The exceptions to this are earlier onset for several anxiety
disorders including specific phobia (9.5 years of age), social
phobia (13.6 years), and agoraphobia (16.8 years). Also, by
definition, childhood separation anxiety disorder has an average age of onset in childhood, at 8.4 years.
The average age of HIV diagnosis for those with particular disorders is presented in column 4. Regardless of type of
psychiatric disorder or substance use disorder, the average
age at HIV diagnosis was in the early 30s, with the average
age being earliest for those with panic disorder (31.7 years),
obsessive–compulsive disorder (OCD) (31.7 years), and
adult separation anxiety disorder (31.4 years), and latest for social phobia (33.3 years), generalized anxiety
disorder (33.1), and all of the substance use disorders
(all > 33.3 years of age).
For the large majority of participants (95.5%) DSM-IV
disorder onset preceded HIV diagnosis, and column 5 presents the average number of years between disorder onset
and HIV diagnosis for this group. On average, mood disorder onset was 15.83 years prior to HIV diagnosis; anxiety
disorder onset was 22.11 years prior to HIV diagnosis; and
substance use disorder onset pre-dated HIV diagnosis by
14.03 years. Among the minority of women (4.5%) whose
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HIV diagnosis predated their DSM-IV disorder onset, as
shown in column 6, onset for mood disorders was an average
of 8.68 years after HIV diagnosis; onset for anxiety disorders
was 9.47 years after HIV diagnosis; and onset of substance
use disorders occurred earliest, an average of 6.80 years after
HIV diagnosis.

12‑Month DSM‑IV Disorders and Severity
Turning next to 12-month DSM-IV disorders, Table 3 presents their prevalence and severity in the WIHS cohort
and corresponding information regarding the US women’s
general household population in the NCS-R. Mood disorder prevalence in the WIHS cohort was 22.1% compared to
10.8% in the general women’s population. Anxiety disorder prevalence was 45.4% in the WIHS compared to 23.2%
in the general population, substance use disorders were 5
times as prevalent in the WIHS compared to the general
women’s population (11.1% vs. 2.2%). The most common
mood disorder was major depressive disorder (20.0%).
The most common anxiety disorders were specific phobias
(22.1%), PTSD (16.6%), and social phobia (13.9%). Among
substance use disorders, drug abuse with or without dependence (5.0%) was more common than alcohol abuse with or
without dependence (2.5%). Specific disorders with noticeably higher prevalence (i.e., 3 or more times) among women
living with HIV than the general women’s population were
dysthymia, bipolar disorders, agoraphobia, OCD, PTSD, and
drug abuse.
Among women with 12-month disorders (bottom row
of Table 3 columns 3–5), over half (57.6%) had at least
one classified as serious, 17.2% as moderate, and 25.1%
as mild in terms of highest severity level. Mood disorders
had the highest percentage of serious classifications (81.1%
of women with any mood disorder had at least one serious
mood disorder), followed by anxiety disorders (51.1%), and
substance use disorders (47.4%). Again in column 3, the specific mood disorder with the highest percentage of serious
classifications was dysthymia (88.2%); the specific anxiety
disorder with the highest percentage of serious classifications was panic disorder (73.3%); and the substance use disorder with the highest percentage of serious classifications
was alcohol abuse (68.0%).
Regarding number of 12-month disorders (Table 3), over
two-fifths (22.6%) of WIHS study participants had three
or more disorders, compared to only 6.6% in the general
women’s population; 11.1% of WIHS participants had 2
disorders, compared to 6.1% in the general population, and
20.2% had one disorder compared to 15.1% in the general
population. In addition, as shown in the 3rd column, there
was a positive relationship between severity and multiple
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Table 1  Demographic and
clinical characteristics of study
population (n = 1027)

3145
n = 1027
Mean (SD) or %(n)

Age, years
Age, quartiles (%)
27–39 years
40–49 years
50–59 years
60 + years
Race (%)
White
Black
Asian
Native American
Other
Hispanic Ethnicity (%)
Education completed (%)
0–11 years
12 years
13–15 years
16 + years
Employed full or part-time (%)
Annual household income ≤ $12,000 (%)
Marital Status (%)
Married/cohabiting
Previously married
Never married
Site (%)
Brooklyn, NY
Bronx, NY
Chicago, IL
Los Angeles, CA
San Francisco, CA
Washington, DC
Taking combination antiretroviral therapy (cART) (%)
CD4 cell count (%)
< 200 mm3
200+ mm3
HIV RNA viral load (%)
> 200 copies/mL
≤ 200 copies/mL
Engaged in HIV risk behaviors over 3 years post-DSM-IV diagnostic assessment (%)
Risky sexual behaviors
Risky substance use behaviors

48.1 (8.7)
16.9 (174)
40.1 (412)
34.5 (354)
8.5 (87)
17.1 (176)
78.4 (805)
1.0 (10)
0.4 (4)
3.1 (32)
18.8 (193)
33.1 (339)
31.9 (327)
26.9 276)
8.1 (84)
31.8 (327)
48.7 (466)
36.9 (379)
31.1 (319)
32.0 (329)
25.2 (259)
17.3 (178)
14.2 (146)
11.7 (120)
15.0 (154)
16.6 (170)
87.0 (893)
11.8 (121)
88.2 (906)
28.8 (295)
71.2 (731)
16.2 (166)
38.1 (390)

SD standard deviation, DSM-IV diagnostic and statistical manual of mental disorders, 4th edition

disorders. Here, among women with three or more disorders,
84.9% had at least one disorder classified as serious on the
severity scale, 58.8% of women with two disorders had at
least one serious disorder, and 26.4% of women with only 1
disorder had a serious disorder.

Comorbidity of Lifetime and 12‑Month Disorders
Comorbid disorders were common (not shown) for both
lifetime and 12-month disorders. Lifetime mood disorders
had the highest rate of comorbidity. Here, the large majority
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Table 2  Lifetime prevalence of DSM-IV disorders in the study population and general US women’s population, and age of onset of DSM-IV disorders and HIV diagnosis in the study population (N = 1027)
DSM-IV diagnostic
category

Study population
prevalence %
(SE)

Mood disorders
Major depressive 32.4 (1.5)
disorder
Dysthymia
9.9 (0.9)
Bipolar I and II
6.6 (0.8)
disorders
Any mood disorder 34.2 (1.5)
Anxiety disorders
Panic disorder
9.0 (8.9)
Agoraphobia
6.2 (0.7)
Specific phobia
28.0 (1.4)
Social phobia
19.7 (1.2)
Generalized anxi- 13.2 (1.0)
ety disorder
Posttraumatic
29.8 (1.4)
stress disorder
Obsessive–com16.0 (1.1)
pulsive disorder
Separation disor- 10.7 (1.0)
der (as child)
Separation disor- 15.9 (1.1)
der (as adult)
Any anxiety dis61.6 (1.5)
order
Substance use disorders
Alcohol w/wo
19.6 (1.2)
dependence
Drug abuse w/wo 49.4 (1.6)
dependence
Any substance use 58.3 (1.5)
disorder
Any DSM-IV
82.6 (1.2)
disorder

General US women’s populationa
prevalence % [SE)

Average age of Average age of
onset, in years HIV diagnosis, in
years

Average # years
disorder preceded
HIV diagnosis
(95.5%)

Average # years HIV
diagnosis preceded
disorder (4.5%)

22.9 (0.6)

20.04

32.35

15.94

8.62

5.1 (0.4)
2.4 (0.3)

19.52
24.28

32.18
32.16

16.66
13.91

6.28
9.08

23.7 (0.6)

20.19

32.46

15.83

8.68

6.2 (0.3)
2.9 (0.3)
15.8 (0.6)
13.0 (0.6)
9.9 (0.4)

23.83
16.80
9.54
13.65
24.44

31.72
32.50
32.34
33.34
33.13

14.76
20.16
24.11
21.34
16.52

9.75
8.89
8.83
8.76
10.11

9.7 (0.7)

23.68

32.29

14.53

8.38

3.1 (0.5)b

20.02

31.69

17.92

8.66

5.4 (0.5)

8.44

32.94

24.51

N/A

7.4 (0.3)

26.78

31.36

12.74

8.60

37.0 (1.2)

13.19

32.64

22.11

9.47

7.5 (0.5)

22.88

33.47

13.88

8.27

4.8 (0.4)

20.43

33.52

14.07

5.49

8.8 (0.5)

20.99

33.54

14.03

6.80

45.7 (1.1)

13.96

33.01

20.20

6.49

SE standard error, w/wo with or without, DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
a

b

National Comorbidity Survey Replication (NCS-R) [49]

From published NCS-R results. This disorder is not available in NCS-R data and is therefore excluded from summary prevalence calculations
(e.g., any mood, anxiety, substance use or DSM-IV disorders)

of women (87.2%) with a lifetime mood disorder also had
a lifetime anxiety disorder, and over two-thirds (68.4%) of
those with a lifetime mood disorder also had a lifetime substance use disorder. In contrast, less than half of women
with lifetime anxiety disorders or substance use disorders
had co-occurring lifetime mood disorders (48.3% and 40.1%
respectively). In addition, lifetime anxiety disorders and
substance use disorders were often comorbid, with 65.9%
and 69.6% of each comorbid with the other, respectively.
Similarly, 12-month mood disorders had the highest rate
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of comorbidity. Here, 79.7% of those with 12-month mood
disorders also had 12-month anxiety disorders. However,
12-month mood disorders were less frequently comorbid
with 12-month substance use disorders (20.3%) given the
relatively low prevalence of 12-month substance use disorders. Similar to lifetime rates, 38.8% of those with 12-month
anxiety disorders also had co-occurring 12-month mood disorders, and 40.4% of those with 12-month substance use
disorders also had 12-month mood disorders. The frequent
co-occurrence of 12-month anxiety disorders and substance
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Table 3  12-Month prevalence of DSM-IV disorders in the study population and general United States women’s population, and DSM disorder
severity in the study population (n = 1027)
DSM-IV diagnostic category

Mood disorders
Major depressive disorder
Dysthymia
Bipolar I and II disorders
Any mood disorder
Anxiety disorders
Panic disorder
Agoraphobia
Specific phobia
Social phobia
Generalized anxiety disorder
Posttraumatic stress disorder
Obsessive–compulsive dis.
Separation disorder (child)
Separation disorder (adult)
Any anxiety disorder
Substance disorders
Alcohol abuse w/wo dep
Drug abuse w/wo dep
Any substance disorder
# of DSM-IV disorders
1 disorder
2 disorders
3 + disorders
Any DSM-IV disorder

Study population
prevalence
n = 1027 % (SE)

General US women’s
populationa prevalence %
(SE)

Severityb of disorder in study populationc
n = 1027
Serious % (SE)

Moderate % (SE)

Mild % (SE)

20.0 (1.2)
9.9 (0.9)
5.2 (0.7)
22.1 (1.3)

10.2 (0.5)
2.9 (0.2)
1.5 (0.2)
10.8 (0.5)

80.0 (2.8)
88.2 (3.2)
60.4 (6.8)
81.1 (2.6)

14.6 (2.5)
7.9 (2.7)
15.1 (5.0)
14.1 (2.3)

5.4 (1.6)
4.0 (1.9)
24.5 (6.0)
4.8 (1.4)

5.8 (0.7)
4.8 (0.7)
22.1 (1.3)
13.9 (1.1)
7.9 (0.8)
16.6 (1.2)
8.1 (0.8)
1.5 (0.4)
5.8 (0.1)
45.4 (1.6)

3.8 (0.3)
1.6 (0.2)
11.7 (0.5)
7.8 (0.5)
5.2 (0.3)
5.2 (0.4)
1.8 (0.5)d
N/A
2.1 (0.2)
23.2 (0.8)

73.3 (5.7)
63.3 (6.9)
19.4 (2.6)
60.8 (4.1)
65.4 (5.3)
47.4 (3.8)
54.2 (5.5)
66.7 (12.6)
70.0 (5.6)
51.1 (2.3)

20.0 (5.2)
14.3 (5.1)
42.3 (3.3)
18.2 (3.2)
13.6 (3.8)
18.1 (3.0)
14.5 (3.9)
13.3 (9.1)
13.3 (4.4)
19.5 (1.8)

6.7 (3.2)
22.4 (6.0)
38.3 (3.2)
21.0 (3.4)
21.0 (4.5)
34.5 (3.6)
31.3 (5.1)
20.0 (10.7)
16.7 ((4.8)
29.4 (2.1)

2.5 (0.5)
5.0 (0.7)
11.1 (1.0)

1.8 (0.3)
0.7 (0.1)
2.2 (0.3)

68.0 (9.5)
66.7 (6.7)
47.4 (4.7)

28.0 (9.2)
15.7 (5.1)
19.3 (3.7)

4.0 (4.0)
17.6 (5.4)
33.3 (4.4)

20.2 (1.2)
11.1 (1.0)
22.6 (1.3)
53.9 (1.6)

15.1 (0.7)
6.1 (0.4)
6.6 (0.4)
27.8 (0.9)

26.4 (3.1)
58.8 (4.6)
84.9 (2.3)
57.6 (2.1)

18.8 (2.7)
26.3 (4.1)
11.6 (2.1)
17.2 (1.6)

54.8 (3.4)
14.9 (3.4)
3.4 (1.2)
25.1 (1.8)

SE standard error, N/A not available, w/wo with or without, DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
a

b
c
d

National Comorbidity Survey Replication (NCS-R) [49]
Severity defined by: work disability, substantial role limitation or impairment, serious violence, or serious suicide attempt
Percentages in the three severity columns are reported as proportions of all cases and sum to 100% across each row

From published NCS-R results. This disorder is not available in NCS-R data and is therefore excluded from summary prevalence calculations
(e.g., any mood, anxiety, substance use or DSM-IV disorders)

use disorders also was observed, since 61.4% of those with
12-month substance use disorders had comorbid 12-month
anxiety disorders.

Individual Correlates of Lifetime and 12‑Month
Disorders
In multivariable logistic regression analysis (Table 4) with
all individual characteristics entered (age, race/ethnic
group, education, employment, income, marital/cohabiting status, CD4+ cell count) and controlling for study site,
lifetime mood disorder was less likely among women who

were working than not working [odds ratio (95% confidence
interval) OR 0.7 (0.5–1.0)]. Lifetime anxiety disorder also
was less likely among women who were working than not
working [OR 0.6 (0.4–0.8)], and more likely among women
with CD4 cell counts higher than 200 [OR 1.5 (1.0–2.3)].
Lifetime substance use disorder was significantly more likely
among women 40 years or older compared to those under
age 40 [age 40–49 years OR 2.2 (1.5–3.3); age 50–59 OR 4.1
(2.6–6.3); age 60 + OR 2.0 (1.1–3.7)]. Lifetime substance
use disorder was less likely among Hispanic women [OR
0.4 (0.4–0.7)] and women in Other race/ethnic groups than
White women [OR 0.4 (0.2–0.9)]; less likely among women
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Table 4  Multivariable sociodemographic and clinical correlates of lifetime and 12-month DSM-IV diagnostic categories, controlling for site
(N = 1027)
Sociodemographic
correlates

DSM-IV cases, odds ratios (95% CI)
Lifetime

12-Month

Mood disorder Anxiety disorder Substance use
OR (95% CI)
OR (95% CI)
disorder
OR (95% CI)

Mood disorder
OR (95% CI)

Anxiety disorder Substance use disorder
OR (95% CI)
OR (95% CI)

Age, years
27–39
1.0 (reference)
40–49
1.4 (0.9–2.1)
50–59
1.2 (0.8–1.9)
+
0.7 (0.4–1.4)
60
Race/ethnicity
Non-Hispanic
1.0 (reference)
White
Non-Hispanic Black 0.7 (0.5–1.1)
Hispanic
1.1 (0.6–1.8)
Other
1.2 (0.6–2.7)
Education completed (years)
0–11
1.0 (reference)
12
1.0 (0.7–1.4)
13–15
1.3 (0.9–1.8)
0.9 (0.5–1.7)
16+
Work status
Not working
1.0 (reference)
Working (part or
0.7 (0.5–1.0)*
full-time)
Income
≤ 12,000
1.0 (reference)
> 12,000
0.8 (0.6–1.1)
Marital status
Married/cohabiting 1.0 (reference)
Previously married 1.0 (0.7–1.4)
Never married
1.0 (0.7–1.4)
CD4 cell count, %
< 200
1.0 (reference)
1.4 (0.9–2.2)
200+

1.0 (reference)
1.0 (0.6–1.4)
1.4 (0.9–2.1)
0.7 (0.4–1.2)

1.0 (reference)
2.2 (1.5–3.3)***
4.1 (2.6–6.3)***
2.0 (1.1–3.7)*

1.0 (reference)
1.3 (0.8–2.2)
1.3 (0.8–2.2)
0.7 (0.3–1.5)

1.0 (reference)
0.8 (0.6–1.2)
1.1 (0.7–1.6)
0.4 (0.2–0.8)*

1.0 (reference)
1.2 (0.6–2.4)
1.2 (0.6–2.6)
0.4 (0.1–1.4)

1.0 (reference)

1.0 (reference)

1.0 (reference)

1.0 (reference)

1.0 (reference)

1.0 (0.7–1.6)
1.5 (0.9–2.4)
0.5 (0.2–1.1)+

0.7 (0.4–1.1)+
0.4 (0.2–0.7)**
0.4 (0.2–0.9)*

0.5 (0.3–0.9)*
0.5 (0.3–0.9)*
0.8 (0.3–2.0)

1.0 (0.7–1.5)
1.2 (0.8–2.0)
0.7 (0.3–1.5)

0.5 (0.3–0.9)*
0.4 (0.2–0.8)*
0.4 (0.1–1.6)

1.0 (reference)
0.8 (0.6–1.1)
0.9 (0.6–1.2)
1.0 (0.6–1.7)

1.0 (reference)
0.9 (0.6–1.3)
0.8 (0.6–1.2)
0.4 (0.2–0.8)**

1.0 (reference)
1.0 (0.7–1.5)
1.1 (0.7–1.7)
0.8 (0.4–1.7)

1.0 (reference)
0.7 (0.5–0.9)*
0.8 (0.6–1.1)
0.8 (0.5–1.4)

1.0 (reference)
0.8 (0.5–1.5)
1.0 (0.5–1.7)
0.7 (0.2–1.9)

1.0 (reference)
0.6 (0.4–0.8)**

1.0 (reference)
0.7 (0.5–0.9)*

1.0 (reference)
1.0 (reference)
0.4 (0.2–0.6)*** 0.5 (0.4–0.7)***

1.0 (reference)
0.6 (0.3–1.1)+

1.0 (reference)
0.9 (0.6–1.2)

1.0 (reference)
.07 (0.5–0.9)*

1.0 (reference)
0.6 (0.4–0.9)*

1.0 (reference)
0.9 (0.6–1.2)

1.0 (reference)
0.4 (0.2–0.6)***

1.0 (reference)
1.3 (0.9–1.8)
1.3 (0.9–1.8)

1.0 (reference)
1.0 (0.7–1.4)
1.1 (0.8–1.6)

1.0 (reference)
1.1 (0.7–1.6)
1.2 (0.8–1.8)

1.0 (reference)
1.4 (1.0–1.9)+
1.2 (0.9–1.7)

1.0 (reference)
0.7 (0.4–1.2)
1.4 (0.8–2.3)

1.0 (reference)
1.5 (1.0–2.3)*

1.0 (reference)
1.1 (0.7–1.7)

1.0 (reference)
1.2 (0.7–1.9)

1.0 (reference)
1.5 (1.0–2.2)+

1.0 (reference)
0.7 (0.4–1.2)

OR odds ratio, CI confidence interval
+

p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001

Models adjusted for study site
DSM-IV diagnostic and statistical manual of mental disorders, 4th edition

with highest levels of education compared to those with the
least education [16 + years OR 0.4 (0.2–0.8)]; less likely
among women who were working compared to those not
working [OR 0.7 (0.5–0.9)]; and less likely among women
with higher income > = $12,000 than lower income [OR
0.7 (0.5–0.9)].
Also in Table 4, 12-month mood disorder was less likely
among Black women [OR 0.5 (0.3-0.9)] and Hispanic/Latina
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women [OR 0.5 (0.3–0.9)]; less likely among employed
women than those not working [OR 0.4 (0.2–0.6)]; and less
likely among women with higher income (i.e., > = $12,000)
than lower income [OR 0.6 (0.4–0.9)]. Anxiety disorder
was less likely among women 60 + years old compared to
those < 40 years old [OR 0.4 (0.2–0.8)]; less likely among
those with a high school or equivalent education compared to
those with less education [OR 0.7 (0.5–0.9)]; and less likely
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among those who were working compared to not working
[OR 0.5 (0.4–0.7)]. Substance use disorders were less likely
among Black women [OR 0.5 (0.3–0.9)] and Hispanic/Latina
women [OR 0.4 (0.2–0.8)], and less likely among women
with higher income [OR 0.4 (0.2–0.6)] than lower income.

Association of 12‑Month Disorders with Subsequent
HIV Risk Behaviors
Our final research question was whether HIV-positive
women with DSM-IV disorders were more likely to engage
in HIV risk behaviors than those without disorders, and
whether specific disorders or disorder combinations were
associated with greater risk. In random effects logistic
Table 5  Results of random
effects logistic regression
models showing the prospective
relationship of 12-month DSMIV mood, anxiety and substance
use disorders to subsequent
HIV risk behaviors over 3 years
(n = 1024 women, n = 4488
study visits)

3149

regression models adjusted for time, age, race (Latina or
White vs. Black), education (< high school), and study
site, we found significant associations between diagnosis
of 12-month psychiatric disorders or substance use disorders, as well as their co-occurrence, and the likelihood of
engaging in subsequent sexual HIV risk behaviors (Table 5).
Associations were particularly strong for women with mood
disorders (major depression, dysthymia, bipolar disorders)
and substance use disorders (alcohol or drug abuse/dependence). For example, compared to their counterparts, women
with 12-month bipolar disorders were over 13 times as likely
[OR 13.6 (4.1–45.3)] and those with drug abuse disorders
over 14 times as likely [OR 14.3 (4.3–47.1)] to engage in
sexual risk behaviors in the ensuing 3 years. There also were

12-month DSM-IV diagnostic category

Risky sexual b ehaviora
16% (166) of women
OR (95% CI)

Mood disorders
Major depressive disorder
5.96 (2.78, 12.77)***
Dysthymia
4.19 (1.58, 11.15)**
Bipolar I and II disorders
13.57 (4.06, 45.34)***
Any mood disorder
5.70 (2.75, 11.86)***
Anxiety disorders
Panic disorder
4.67 (1.40, 15.65)*
Agoraphobia
1.99 (0.49, 8.17)
Specific phobia
2.54 (1.20, 5.38)**
Social phobia
3.74 (1.57, 8.91)***
Generalized anxiety disorder
1.87 (0.57, 6.06)
Posttraumatic stress disorder
2.30 (1.01, 5.20)*
Obsessive–compulsive dis.
5.26 (1.88, 14.69)**
Separation disorder (adult)
3.40 (1.03, 11.21)*
Any anxiety disorder
4.46 (2.26, 8.78)***
Substance use disorders
Alcohol abuse
6.20 (1.17, 32.80)***
Alcohol dependence
9.09 (1.67, 49.64)***
Drug abuse
14.28 (4.30, 47.14)***
Drug dependence
11.40 (3.79, 34.30)***
Any substance use disorder
6.60 (2.64, 16.50)***
Co-occurring psychiatric + substance use disorders
Any mood + any substance use
15.88 (4.35, 57.92)***
Any anxiety + any substance use
9.54 (3.20, 28.44)***
Any psychiatric + any substance use
10.43 (3.67, 29.67)***

Risky alcohol/drug useb
38% (390) of women
OR (95% CI)
4.43 (1.89, 10.39)**
1.79 (0.58, 5.56)
1.70 (0.39, 7.45)
4.52 (2.02, 10.12)***
2.80 (0.67, 11.69)
1.96 (0.41, 9.42)
1.78 (0.78, 4.08)
2.14 (0.80, 5.71)
3.04 (0.87, 10.62)
1.58 (0.62, 4.02)
1.34 (0.38, 4.79)
1.72 (0.41, 7.29)
2.84 (1.40, 5.76)**
69.05 (8.85, 538.76)***
51.14 (6.44, 406.17)***
67.93 (15.26, 302,36)***
20.79 (5.62, 76.83)***
48.53 (16.99, 138.53)***
23.42 (4.87, 112.58)***
16.96 (4.66, 61.68)***
19.57 (5.68, 67.42)***

OR odds ratio, CI confidence interval, DSM-IV diagnostic and statistical manual of mental disorders, 4th
edition
*p < 0.05, **p < 0.01, ***p < 0.001
Models adjusted for time, age (in 10 year increments), race (Latina or White vs. Black), education (< high
school vs. high school or more) and study site (Brooklyn as reference)
Three women did not have study visits with behavioral data subsequent to the WMH-CIDI assessment

a

b

Exchanged money for sex/drugs/shelter, multiple male partners, or receptive anal sex

Any illicit drug use or consumption of > 7 National Institute on Alcohol Abuse and Alcoholism standard
drinks per week
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significant associations with most anxiety disorders including panic, specific phobia, social phobia, PTSD, OCD, and
adult separation anxiety disorder. Agoraphobia and generalized anxiety disorder were not associated with subsequent sexual risk behaviors. Women with any psychiatric
disorder and co-occurring substance use disorder were over
10 times as likely to engage in risky sexual behaviors [OR
10.4 (3.7–29.7)], and women with any mood disorder and
co-occurring substance use disorder were over 15 times as
likely [OR 15.9 (4.4–57.9)].
By definition, strong associations were expected between
substance use disorders and the subsequent occurrence of
HIV drug and alcohol risk behaviors, and these are evident
in Table 5. However, women with any mood disorder or
any anxiety disorder also were more likely to engage in
HIV drug and/or alcohol risk behaviors than others [OR 4.5
(2.0–10.1), and OR 2.8 (1.4–5.8), respectively].

Discussion
Results from this investigation confirm those of the only
other large scale assessment of behavioral health disorders
among adults living with HIV, which was conducted almost
three decades ago. The lifetime and 12-month prevalence of
behavioral health disorders in this US cohort study of HIVpositive women far exceeded that of the general population
of US women, with mood disorders, anxiety disorders, and
substance use disorders being two- to three-fold more common in our cohort. Also, the number of DSM-IV disorders
was higher in our cohort than in the general US women’s
population, with 23% having 3 or more 12-month disorders
compared to only 7% in the general population. Another
noteworthy difference was in the distribution of lifetime
disorders, with substance use disorders being second most
common in our cohort, while they were least common in the
general women’s population.
This study also found a high degree of comorbidity across
mood disorders, anxiety disorders, and substance use disorders. This has been noted in studies of the general population
[50, 51], but the large extent to which it characterizes HIVpositive women is evident for the first time in our findings.
Almost all women with lifetime mood disorders had cooccurring lifetime anxiety disorders (87%) while over twothirds (68%) also had lifetime substance use disorders. Thus
the occurrence of no behavioral health disorders or only one
disorder was uncommon in this longitudinal study cohort.
Among women with current 12-month disorders, the large
majority with mood disorders also had a co-occurring anxiety disorder (80%), and of those with 12-month substance
use disorders, almost two-thirds (61%) had a co-occurring
anxiety disorder. This extremely high level of comorbidity requires complex treatment protocols and has negative
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prognostic implications for psychological health, medical
well-being, and longevity [52, 53].
We found that sociodemographic characteristics including education, income, being Black, and being Latina were
negatively associated with likelihood of behavioral health
disorders which mirrors prior CIDI research on the general
population [8]. Employed women were less likely to have a
recent behavioral health disorder, which parallels the wellestablished negative relationship between behavioral health
disorders and employment [54].
Finally, this study documented significant associations
between behavioral health disorders and HIV sexual and
drug use risk behaviors in the 3 years following diagnostic
assessment. Risky sexual behaviors were more likely among
women with any 12-month disorder, and were especially
likely among women with diagnoses of bipolar disorder or
drug use disorders. In addition, a 12-month diagnosis of
co-occurring mood disorder with substance use disorder or
co-occurring anxiety disorder with substance use disorder
increased the likelihood of subsequent risky drug and alcohol use. Drug and alcohol risk behaviors can be associated
with sexual risk behaviors, both because women exchange
sex for material goods and because decision making capacity
is diminished when under the influence. Thus, our results
suggest that interventions addressing behavioral health may
also prevent subsequent HIV risk behaviors. For example, it
may be beneficial to tailor HIV risk reduction interventions
for women with disorders in which impulse control can be
problematic, such as bipolar and substance use disorders
[55], since these had the highest odds ratios for HIV transmission behaviors. Similarly, interventions might effectively
be tailored for women with high levels of negative affect and
associated risk taking [56], such as major depression and
obsessive–compulsive disorder [57], since our findings also
showed moderately high odds ratios for these disorders and
HIV risk behaviors.
A number of study limitations should be noted. The study
cohort may not be generalizable to the US population of
women living with HIV, and the cohort may not represent
younger women or those who are not engaged in HIV care.
In addition, space limitations prevent us from identifying
associations between behavioral health disorders and factors such as income, race, education, and other demographic
variables in the NCS-R comparator data. Another limitation
is use of self-report for key study variables such as frequency
and types of HIV risk behaviors. WMH-CIDI assessments
were not available for the entire cohort, and this may have
biased our results, especially those related to women who
spoke only Spanish or those who were employed. Finally,
we do not consider the effects of receiving treatment for
behavioral health disorders or HIV/AIDS since these are
the subject of a separate manuscript. Study strengths include
the large number of participants, the multisite nature of the
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cohort, the diversity of geographic site locations, inclusion
of a comparison population, and use of diagnostic interviews
instead of screening tools.
The major implication of these results is the critical
need for integrated health and behavioral health care and
the importance of addressing the challenges currently faced
in organizing and providing it to women living with HIV
[58]. Studies have shown that screening HIV-positive adults
and referring them to mental health and substance abuse
treatment is largely ineffective [59], especially when psychiatric disorders and substance use disorders co-occur [60].
Moreover, the high rate of co-morbidity among HIV-positive women may make screening for discrete conditions an
ineffective approach. Further, because women from diverse
cultures experience and express behavioral health symptoms and role impairment differently [61, 62], screening
and assessment must also be sensitive to African American,
Hispanic/Latina, and other cultures [63, 64], as well as to the
intersection of trauma with poor mental health and substance
use in the lives of many HIV-positive women [65, 66].
The fact that women living with HIV have multiple cooccurring behavioral health disorders of high severity poses
serious challenges to clinicians seeking to provide coordinated care. The term “health complexity” has been coined
to refer to individuals with multiple co-morbid medical and
behavioral health conditions whose care is complicated by
personal and social factors such as housing, ethnicity, social
support, and poverty, as well as by health system factors
such as inadequate insurance coverage, gaps in specialty
care, and segregated medical and behavioral health treatment [67, 68]. This characterization fits our study population
especially well, and calls attention to specific challenges.
One such challenge is a lack of evidence-based treatment
options for people with co-occurring substance use disorders, mood disorders, and anxiety disorders. Research shows
that treating only one of these disorders does not improve
the others, and that when only one is treated, significant
distress and disability typically remain [52, 69]. An alternative approach is concurrent treatment, in which separate
therapies are delivered at the same time. For example, studies support combining cognitive behavioral therapy for
substance use disorders with exposure therapy or cognitive restructuring for anxiety disorders [69]. Research also
supports the use of integrated treatment approaches, where
services that target multiple conditions simultaneously are
delivered in a coordinated fashion. For example, a recent
trial combining sertraline and naltrexone for treating cooccurring depression and alcohol dependence was effective
in reducing depression and promoting alcohol abstinence
[70]. However, development and evaluation of these models
are in relatively early stages, meaning that we lack effective
treatments for co-occurring behavioral health disorders [52],
especially among women [71].
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A second level of challenges involves integrating medical and behavioral health treatment in the face of multiple
co-occurring conditions of each type along with personal
and health system factors. Here again, there are promising
models that can be applied to HIV-positive women with
multi-morbidities. One is the collaborative care model in
the primary care setting, where case managers or nurse practitioners work with primary care providers, mental health
professionals, and substance use treatment specialists in a
patient-centered, socioecologically focused approach that
incorporates community and health system factors [72, 73].
Another model is integrated complex case management,
which involves the longitudinal, relationship-based use of
biopsychosocial and health system-based care plans that
are complexity-focused, with few handoffs, and escalation
of care as well as discharge based on clinical, functional,
and cost outcome measurement [68]. Application of these
models in the HIV field is relatively new, but they offer great
promise [74–76], especially when designed to also address
HIV-positive women’s key structural determinants including violence against women and economic insecurity [26].
In addition to the human costs of co-occurring HIV
infection and behavioral health disorders, the financial
costs are considerable. One recent analysis of patients in
the Kaiser Permanente Northern California integrated health
care system [77], reported that mean total healthcare costs
were higher in HIV-positive patients who were diagnosed
with psychiatric disorders and substance use disorders (per
patient per year average of $32,881) compared to HIV-positive patients without these comorbidities (per patient per
year average of $29,142), and that this difference remained
significant after controlling for confounding individual characteristics. Taking this one step further, the strong association between having psychiatric disorders and substance use
disorders and engaging in HIV risk behaviors increases the
chances of viral transmission and creation of new infections,
while lessening the positive potential of treatment as prevention [78], incurring additional societal costs and individual
burdens.
We conclude that the development, testing, and diffusion
of evidence-based, culturally sensitive, trauma-informed
models of complex, integrated physical and behavioral
health care should be a key public health strategy for HIV
prevention and control. Also needed is further investigation of how race/ethnicity, income, education, poverty, and
trauma affect the experience and expression of behavioral
health disorders among women living with HIV. Finally,
the impact of treatment for mental health and substance use
disorders on the likelihood of engaging in HIV risk behaviors requires further exploration, in order to more effectively
integrate behavioral health and antiretroviral therapies.

13

3152
Acknowledgements This research was funded by grant number
1R01MH089830 from the National Institute of Mental Health (NIMH).
Some data used in the analysis were collected by the Women’s Interagency HIV Study (WIHS). The contents of this publication are solely
the responsibility of the authors and do not represent the official views
of the National Institutes of Health (NIH). WIHS (Principal Investigators): UAB-MS WIHS (Michael Saag, Mirjam-Colette Kempf, and
Deborah Konkle-Parker), U01-AI-103401; Atlanta WIHS (Ighovwerha
Ofotokun and Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff
and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge
Cohen and Audrey French), U01-AI-034993; Metropolitan Washington WIHS (Mary Young and Seble Kassaye), U01-AI-034994; Miami
WIHS (Margaret Fischl and Lisa Metsch), U01-AI-103397; UNC
WIHS (Adaora Adimora), U01-AI-103390; Connie Wofsy Women’s
HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat,
and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590;
Southern California WIHS (Alexandra Levine and Marek Nowicki),
U01-HD-032632 (WIHS I – WIHS IV). The WIHS is funded primarily
by the National Institute of Allergy and Infectious Diseases (NIAID),
with additional co-funding from the Eunice Kennedy Shriver National
Institute of Child Health and Human Development (NICHD), the
National Cancer Institute (NCI), the National Institute on Drug Abuse
(NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by
the National Institute of Dental and Craniofacial Research (NIDCR),
the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the
National Institute on Deafness and other Communication Disorders
(NIDCD), and the NIH Office of Research on Women’s Health. WIHS
data collection is also supported by UL1-TR000004 (UCSF CTSA) and
UL1-TR000454 (Atlanta CTSA).
Funding This study was funded by grant number 1R01MH089830
from the National Institute of Mental Health (NIMH). Some data used
in the analysis were collected by the Women’s Interagency HIV Study
(WIHS). The contents of this publication are solely the responsibility
of the authors and do not represent the official views of the National
Institutes of Health (NIH). WIHS (Principal Investigators): UAB-MS
WIHS (Michael Saag, Mirjam-Colette Kempf, and Deborah KonkleParker), U01-AI-103401; Atlanta WIHS (Ighovwerha Ofotokun and
Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn Anastos),
U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey
French), U01-AI-034993; Metropolitan Washington WIHS (Mary
Young and Seble Kassaye), U01-AI-034994; Miami WIHS (Margaret
Fischl and Lisa Metsch), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie Wofsy Women’s HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien),
U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Alexandra Levine and Marek Nowicki), U01-HD-032632
(WIHS I – WIHS IV). The WIHS is funded primarily by the National
Institute of Allergy and Infectious Diseases (NIAID), with additional
co-funding from the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD), the National Cancer
Institute (NCI), the National Institute on Drug Abuse (NIDA), and the
National Institute on Mental Health (NIMH). Targeted supplemental
funding for specific projects is also provided by the National Institute
of Dental and Craniofacial Research (NIDCR), the National Institute
on Alcohol Abuse and Alcoholism (NIAAA), the National Institute
on Deafness and other Communication Disorders (NIDCD), and the
NIH Office of Research on Women’s Health. WIHS data collection is
also supported by UL1-TR000004 (UCSF CTSA) and UL1-TR000454
(Atlanta CTSA).

13

AIDS and Behavior (2018) 22:3141–3154
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativeco
mmons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.

References
1. Arendt G. Affective disorders in patients with HIV infection. CNS
Drug Rev. 2006;20(6):507–18.
2. Chander G, Himelhoch S, Moore RD. Substance abuse
and psychiatric disorders in HIV-positive patients. Drugs.
2006;66(6):769–89.
3. Klinkenberg WD, Sacks S. The HIV/AIDS treatment adherence, health outcomes and cost study group. Mental disorders
and drug abuse in persons living with HIV/AIDS. AIDS Care.
2004;16(sup1):22–42.
4. Bozzette SA, Berry SH, Duan N, et al. The care of HIVinfected adults in the United States. New Engl J Med.
1998;339(26):1897–904.
5. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus–
infected adults in the United States. Arch Gen Psychiatry.
2001;58(8):721–8.
6. Orlando M, Burnam MA, Beckman R, Morton SC, London AS,
Bing EG, Fleishman JA. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons
receiving care for HIV: results from the HIV cost and services
utilization study. Int J Method Psychiatr. 2002;11(2):75–82.
7. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of
DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.
8. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the
National Comorbidity Survey Replication. Arch Gen Psychiatry.
2005;62(6):617–27.
9. Gala C, Pergami A, Catalan J, et al. The psychosocial impact of
HIV infection in gay men, drug users and heterosexuals. Controlled investigation. Br J Psychiatry. 1993;163(5):651–9.
10. Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence
and comorbidity of psychiatric diagnoses based on reference
standard in an HIV+ patient population. Psychosom Med.
2008;70(4):505–11.
11. Lyketsos CG, Hanson A, Fishman M, McHugh PR, Treisman GJ.
Screening for psychiatric morbidity in a medical outpatient clinic
for HIV infection: the need for a psychiatric presence. Int J Psychiatr Med. 1994;24(2):103–13.
12. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata
MM. The effect of mental illness, substance use, and treatment
for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDs.
2008;22(3):233–43.
13. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir
Immune Defic Syndr. 2006;42(3):298–306.
14. Rabkin JG. Prevalence of psychiatric disorders in HIV illness. Int
Rev Psychiatry. 1996;8:157–66.
15. Dew MA, Reynolds CF, Houck PR, et al. Temporal profiles of
the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry.
1997;54(11):1016–24.

AIDS and Behavior (2018) 22:3141–3154
16. Dausey DJ, Desai RA. Psychiatric comorbidity and the prevalence
of HIV infection in a sample of patients in treatment for substance
abuse. J Nerv Ment Dis. 2003;191(1):10–7.
17. DeLorenze GN, Tsai AL, Horberg MA, Quesenberry CP. Cost of
care for HIV-infected patients with co-occurring substance use
disorder or psychiatric disease: report from a large, integrated
health plan. AIDS Res Treat. 2014;24:1–9.
18. Burnam MA, Bing EG, Morton SC, et al. Use of mental health
and substance abuse treatment services among adults with HIV
in the United States. Arch Gen Psychiatry. 2001;58(8):729–36.
19. Galvan FH, Burnam MA, Bing EG. Co-occurring psychiatric
symptoms and drug dependence or heavy drinking among HIVpositive people. J Psychoact Drugs. 2003;35(sup1):153–60.
20. DeLorenze GN, Satre DD, Quesenberry CP Jr, Tsai AL, Weisner
CM. Mortality after diagnosis of psychiatric disorders and cooccurring substance use disorders among HIV-infected patients.
AIDS Patient Care STDs. 2010;24(11):705–12.
21. Malee K, Mellins CA, Huo Y, et al. Prevalence, incidence and
persistence of psychiatric and substance use disorders among
mothers living with HIV. J Acquir Immune Defic Syndr.
2014;65(5):526–34.
22. Parhami I, Fong TW, Siani A, Carlotti C, Khanlou H. Documentation of psychiatric disorders and related factors in a large sample
population of HIV-positive patients in California. AIDS Behav.
2013;17:2792–801.
23. Cook JA, Grey DD, Burke-Miller JK, et al. Illicit drug use,
depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend.
2007;89(1):74–81.
24. Cook RL, Zhu F, Belnap BH, et al. Longitudinal trends in hazardous alcohol consumption among women with human immunodeficiency virus infection, 1995–2006. Am J Epidemiol.
2009;169(8):1025–32.
25. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multi-center cohort of HIV-1
positive women. AIDS. 2008;22(11):1355–63.
26. Edwards A. Recognizing the influence of social determinants on
HIV risk behaviors and the need for structural interventions to prevent HIV in women. J Health Dispar Res Pract. 2015;7(7):10–25.
27. Sharpe TT, Voûte C, Rose MA, Cleveland J, Dean HD, Fenton K.
Social determinants HIV/AIDS and sexually transmitted diseases
among black women: implications for health equity. J Womens
Health. 2012;21(3):249–54.
28. Cook JA, Burke-Miller JK, Grey DD, Coccohoba J, Liu C,
Schwartz R, Golub ET, Anastos K, Steigman PJ, Cohen MH. Do
HIV-positive women receive depression treatment that meets best
practice guidelines? AIDS Behav. 2014;18(6):1094–102.
29. Otto-Salaj LL, Kelly JA, Stevenson LY, Hoffmann R, Kalichman
SC. Outcomes of a randomized small-group HIV prevention intervention trial for people with serious mental illness. Community
Ment Health J. 2001;37(2):123–44.
30. Santelli JS, Robin L, Brener ND, Lowry R. Timing of alcohol and
other drug use and sexual risk behaviors among unmarried adolescents and young adults. Fam Plann Perspect. 2001;33:200–5.
31. Metsch LR, McCoy CB, Lai S, Miles C. Continuing risk behaviors
among HIV-seropositive chronic drug users in Miami, Florida.
AIDS Behav. 1998;2(2):161–9.
32. Brewer TH, Zhao W, Metsch LR, Coltes A, Zenilman J. High-risk
behaviors in women who use crack: knowledge of HIV serostatus
and risk behavior. Ann Epidemiol. 2007;17(7):533–9.
33. Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and HIV risk behaviors among patients
in a sexually transmitted disease clinic. Am J Psychiatry.
2004;161(5):912–4.

3153
34. Staton-Tindall M, Harp KL, Minieri A, et al. An exploratory study
of mental health and HIV risk behavior among drug-using rural
women in jail. Psychiatr Rehabil J. 2015;38(1):45–54.
35. Campsmith ML, Nakashima AK, Jones JL. Association between
crack cocaine use and high-risk sexual behaviors after HIV diagnosis. J Acquir Immune Defic Syndr. 2000;25(2):192–8.
36. Newville H, Haller DL. Psychopathology and transmission risk behaviors in patients with HIV/AIDS. AIDS Care.
2010;22(10):1259–68.
37. Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I.
Depression severity and drug injection HIV risk behaviors. Am J
Psychiatry. 2003;160(9):1659–62.
38. Miles DR, Svikis DS, Kulstad JL, Haug NA. Psychopathology
in pregnant drug-dependent women with and without comorbid
alcohol dependence. Alcohol Clin Exp Res. 2001;25(7):1012–7.
39. Mota NP, Cox BJ, Katz LY, Sareen J. Relationship between mental disorders/suicidality and three sexual behaviors: results from
the National Comorbidity Survey Replication. Arch Sex Behav.
2010;39(3):724–34.
40. Plotzker RE, Metzger DS, Holmes WC. Childhood sexual and
physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: a potential mediating pathway. Am J Addict. 2007;16(6):431–8.
41. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis
of high-risk sexual behavior in persons aware and unaware
they are infected with HIV in the United States: implications
for HIV prevention programs. J Acquir Immune Defic Syndr.
2005;39(4):446–53.
42. Latka MH, Wilson TE, Cook JA, Bacon MC, Richardson JL,
Sohler N, Cohen MH, Greenblatt RM, Andreopoulis E, Vlahov D.
Impact of drug treatment on subsequent sexual risk behavior in a
multisite cohort of drug-using women: a report from the Women’s
Interagency HIV Study. J Subst Abuse Treat. 2005;29(4):329–37.
43. Crepaz N, Marks G, Liau A, Mullins MM, Aupont LW, Marshall
KJ, Jacobs ED, Wolitski RJ. HIV/AIDS Prevention Research Synthesis (PRS) Team. Prevalence of unprotected anal intercourse
among HIV-diagnosed MSM in the United States: a meta-analysis.
AIDS. 2009;23(13):1617–29.
44. Meade CS, Kershaw TS, Hansen NB, Sikkema KJ. Long-term
correlates of childhood abuse among adults with severe mental
illness: adult victimization, substance abuse, and HIV sexual risk
behavior. AIDS Behav. 2009;13(2):207–16.
45. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA,
Miotti P, Young M, Greenblatt R, Sacks H, Feldman J. The women’s interagency HIV study. Epidemiology. 1998;9(2):117–25.
46. Bacon MC, von Wyl V, Alden C, et al. The Women’s Interagency
HIV Study: an observational cohort brings clinical sciences to the
bench. Clin Diagn Lab Immunol. 2005;12(9):1013–9.
47. Kessler RC, Üstün TB. The world mental health (WMH) survey
initiative version of the world health organization (WHO) composite international diagnostic interview (CIDI). Int J Methods
Psychiatr Res. 2004;13(2):93–121.
48. US Preventive Services Task Force. Screening and behavioral
counseling interventions in primary care to reduce alcohol misuse:
recommendation statement. Ann Intern Med. 2004;140(7):554–6.
49. Alegría M, Jackson JS, Kessler RC, Takeuchi D. Collaborative
Psychiatric Epidemiology Surveys (CPES), 2001–2003 [United
States]. ICPSR20240-v8. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor]. 2015;201512-09. http://doi.org/10.3886/ICPSR20240.v8.
50. Back SE, Brady KT. Anxiety disorders with comorbid substance
use disorders: diagnostic and treatment considerations. Psychiatr
Ann. 2008;38(11):724–9.

13

3154
51. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and cooccurrence of substance use disorders and independent mood
and anxiety disorders: results from the national epidemiologic
survey on alcohol and related conditions. Arch Gen Psychiatry.
2004;61(8):807–16.
52. Pettinati HM, O’Brien CP, Dundon WD. Current status of cooccurring mood and substance use disorders: a new therapeutic
target. Am J Psychiatry. 2013;170(1):23–30.
53. Sagman D, Tohen, M. Comorbidity in bipolar disorder: The complexity of diagnosis and treatment. Psychiatric Times 2009. http://
www.psychi atric times .com/bipola r-disord er/comorb idity -bipola rdisorder. Accessed 10 Oct 2016.
54. Cook JA, Burke-Miller JK, Roessel E. Long-term effects of evidence-based supported employment on earnings and on SSI and
SSDI participation among individuals with psychiatric disabilities. Am J Psychiatry. 2016;173(10):1007–14.
55. Reddy LF, Junghee L, Davis MC, Altschuler L, et al. Impulsivity
and risk taking in bipolar disorder and schizophrenia. Neuropsychopharmacology. 2014;39:456–63.
56. Desrichard O, Denarie V. Sensation seeking and negative affectivity as predictors of risky behaviors: a distinction
between occasional versus frequent risk-taking. Addict Behav.
2005;30(7):1449–53.
57. Abramawitz JS, Whiteside S, Lynam D, Kalsy S. Is thought-action
fusion specific to obsessive-compulsive disorder?: a medicating
role of negative affect. Behav Res Ther. 2003;41(9):1069–79.
58. Cournos F, McKinnon K, Wainberg M. What can mental health
interventions contribute to the global struggle against HIV/AIDS.
World Psychiatry. 2005;4(3):135–41.
59. Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with
HIV/AIDS. J Antimicrob Chemother. 2009;63(4):636–40.
60. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use
comorbidities in people infected with HIV who use drugs. Lancet.
2010;376(9738):367–87.
61. Nair P, Schuler ME, Black MM, Kettinger L, Harrington D.
Cumulative environmental risk in substance abusing women:
early intervention, parenting stress, child abuse potential and child
development. Child Abuse Negl. 2003;27(9):997–1017.
62. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald
S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine
JP. Cross-national epidemiology of major depression and bipolar
disorder. JAMA. 1996;276(4):293–9.
63. Alegria M, Jackson JS, Kessler RC, Takeuchi D. Collaborative
Psychiatric Epidemiology Surveys (CPES), 2001–2003 [United
States]. ICPSR20240-v6. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor]. 2008:06–19.
64. Delgado PL, Alegría M, Cañive JM, et al. Depression and
access to treatment among US Hispanics: review of the

13

AIDS and Behavior (2018) 22:3141–3154

65.

66.

67.

68.

69.
70.

71.

72.
73.
74.

75.
76.
77.
78.

literature and recommendations for policy and research. Focus.
2006;4(1):38–47.
Johnson SD, Cunningham-Williams RM, Cottler LB. A tripartite of HIV-risk for African American women: the intersection
of drug use, violence, and depression. Drug Alcohol Depend.
2003;70(2):169–75.
Weiss JJ, Morgello S. Psychiatric management of HIV/HCVcoinfected patients beginning treatment for hepatitis C virus
infection: survey of provider practices. Gen Hosp Psychiatry.
2009;31(6):531–7.
Grembowski D, Schaefer J, Johnson KE, Fischer H, Moore SL,
Tai-Seale M, Ricciardi R, Fraser JR, Miller D, LeRoy L. A conceptual model of the role of complexity in the care of patients with
multiple chronic conditions. Med Care. 2014;52:S7–14.
Kathol RG, Knutson KH, Dehnel PJ. Health Complexity and the
Interaction Between Physical and Behavioral Health Conditions
in Children and Youth. In Physician’s Guide 2016 (pp. 51–77).
Springer International Publishing.
McHugh RK. Treatment of co-occurring anxiety disorders and
substance use disorders. Harv Rev Psychiatry. 2015;23(2):99–111.
Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind,
placebo-controlled trial combining sertraline and naltrexone for
treating co-occurring depression and alcohol dependence. Am J
Psychiatry. 2010;167(6):668–75.
Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial
of behavioral interventions for women with co-occurring
PTSD and substance use disorders. J Consult Clin Psychol.
2009;77(4):607–19.
Katon W, Von Korff M, Lin E, Simon G. Rethinking practitioner
roles in chronic illness: the specialist, primary care physician, and
the practice nurse. Gen Hosp Psychiatry. 2001;23(3):138–44.
Simon G. Collaborative care for depression. BMJ.
2006;332:249–50.
Cheever LW, Kresina TF, Cajina A, Lubran R. A model federal collaborative to increase patient access to buprenorphine
treatment in HIV primary care. J Acquir Immune Defic Syndr.
2011;56:S3–6.
Curran GM, Pyne J, Fortney JC, et al. Development and implementation of collaborative care for depression in HIV clinics.
AIDS Care. 2011;23(12):1626–36.
Ojikutu B, Holman J, Kunches L, et al. Interdisciplinary HIV care
in a changing healthcare environment in the USA. AIDS Care.
2014;26(6):731–5.
Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer
D, Fava M. The STAR* D study: treating depression in the real
world. Cleve Clin J Med. 2008;75:57–66.
Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99–105.

